|
gptkbp:instanceOf
|
gptkb:company
|
|
gptkbp:acquiredBy
|
gptkb:CareFusion_(2015)
C. R. Bard (2017)
|
|
gptkbp:alsoKnownAs
|
gptkb:BD
|
|
gptkbp:annualReport
|
https://investors.bd.com/financials/annual-reports/default.aspx
|
|
gptkbp:category
|
gptkb:insurance
Fortune 500 company
conglomerate
medical equipment manufacturer
|
|
gptkbp:CEO
|
gptkb:Tom_Polen
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:division
|
gptkb:BD_Interventional
gptkb:BD_Life_Sciences
gptkb:BD_Medical
|
|
gptkbp:founded
|
1897
|
|
gptkbp:founder
|
gptkb:Fairleigh_S._Dickinson
gptkb:Maxwell_Becton
|
|
gptkbp:headquartersLocation
|
gptkb:Franklin_Lakes,_New_Jersey,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Becton Dickinson
|
|
gptkbp:industry
|
medical device
|
|
gptkbp:ISIN
|
US0758871091
|
|
gptkbp:listedOn
|
gptkb:S&P_500
|
|
gptkbp:logo
|
Becton Dickinson logo.svg
|
|
gptkbp:market
|
global
|
|
gptkbp:notableProduct
|
needles
biosciences instruments
diagnostic systems
infusion therapy devices
syringes
|
|
gptkbp:numberOfEmployees
|
2023
~77,000
|
|
gptkbp:products
|
gptkb:research_institute
medical devices
diagnostic products
|
|
gptkbp:publiclyTraded
|
true
|
|
gptkbp:revenue
|
2023
~$19 billion (2023)
|
|
gptkbp:stockExchange
|
gptkb:NYSE
|
|
gptkbp:stockSymbol
|
gptkb:BDX
|
|
gptkbp:subsidiary
|
gptkb:C._R._Bard
gptkb:CareFusion
|
|
gptkbp:website
|
https://www.bd.com
|
|
gptkbp:bfsParent
|
gptkb:Peter_Arduini
|
|
gptkbp:bfsLayer
|
5
|